Abstract
Rodents learn to associate the rewarding effects of drugs with the environment in which they are encountered and, subsequently, will display a conditioned place preference (CPP) for that environment. Cocaine-induced CPP is generally thought to be mediated through inhibition of the dopamine transporter and the consequent increase in extracellular dopamine. However, here we report that dopamine-deficient (DD) mice formed a CPP for cocaine that was not blocked by a dopamine D1-receptor antagonist. Fluoxetine, a serotonin transporter (SERT) inhibitor, produced CPP in DD, but not control mice, suggesting that serotonin mediates cocaine CPP in DD mice. Inhibition of dopamine neuron firing by pretreatment with quinpirole, a dopamine D2-receptor agonist, blocked both cocaine- and fluoxetine-induced CPP in DD mice. These findings are consistent with the hypothesis that, in the absence of dopamine, cocaine-mediated SERT blockade activates dopamine neurons, which then release some other neurotransmitter that contributes to cocaine reward in DD mice.
- cocaine
- conditioned place preference
- dopamine
- dopamine-deficient
- dopamine transporter
- serotonin transporter
Introduction
Cocaine produces its effects on the CNS through blockade of the plasma membrane monoamine-reuptake transporters and the consequent increase in monoamine signaling. Although cocaine blocks the dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters with comparable efficacy (Rothman and Baumann, 2003), most of the psychoactive effects of cocaine have been attributed to DAT blockade. For instance, the reinforcing properties of monoamine-transporter blockers strongly correlate with their ability to bind to DAT (Ritz et al., 1987). Treatment with dopamine-receptor antagonists or dopamine-specific lesions can inhibit the acquisition or expression of cocaine-induced conditioned place preference (CPP) and alter cocaine self-administration responses (Pettit et al., 1984; Cervo and Samanin, 1995; Pruitt et al., 1995) (for review, see Pierce and Kumaresan, 2006). However, other studies have failed to show clear effects of dopamine-receptor antagonists or dopamine-neuron lesions on reward-related cocaine responses (Spyraki et al., 1982). Moreover, some specific DAT blockers produce little or no reinforcing effects despite causing large increases in dopamine signaling (Rothman and Glowa, 1995).
Nondopaminergic manipulations can also modify the reinforcing properties of cocaine. In particular, serotonin signaling clearly modulates cocaine responses. For example, 5-HT1b-receptor knock-out (KO) mice display enhanced cocaine self-administration (Rocha et al., 1998b), and 5-HT1b agonist treatment (Parsons et al., 1998) or viral-mediated 5-HT1b expression in nucleus accumbens (NAc) sensitizes animals to cocaine reward (Neumaier et al., 2002).
Studies using monoamine-transporter knock-out mice suggest an overlapping role for monoamine signaling in mediating cocaine CPP. DAT-KO mice continue to self-administer cocaine and display cocaine CPP (Rocha et al., 1998a; Sora et al., 1998). Although SERT-KO and NET-KO mice also readily develop cocaine CPP (Sora et al., 1998; Xu et al., 2000), DAT/SERT double-KO mice do not (Sora et al., 2001), suggesting that cocaine-mediated DAT or SERT blockade is sufficient for CPP but that alone, neither is necessary for cocaine reward. Unexpectedly, extracellular dopamine levels still increase in the NAc after cocaine administration to DAT-KO mice (Carboni et al., 2001; Mateo et al., 2004); the authors suggest that although DAT is not a necessary substrate for cocaine-induced reward, dopamine signaling may still be an essential mediator.
Here we address the question of whether dopamine is essential for cocaine-induced CPP by taking advantage of a dopamine-deficient (DD) mouse model in which tyrosine hydroxylase, the rate-limiting enzyme for catecholamine biosynthesis, is inactivated in dopamine neurons but not other catecholaminergic neurons (Zhou and Palmiter, 1995). We have previously shown that DD mice are capable of learning and expressing a CPP for morphine in the dopamine-depleted state (Hnasko et al., 2005). Those experiments demonstrated that the acute increase in dopamine signaling normally produced by morphine is not required for the hedonic impact (“liking”) of morphine, nor for mice to form a conditioned association (“learning”) (Berridge, 2007). In this study, we show that DD mice are also able to express a CPP for cocaine independently of dopamine release. Furthermore, we show that in the absence of dopamine, cocaine CPP is mediated by SERT blockade, but we suggest that this cocaine CPP may still be dependent on dopamine neuron activity.
Materials and Methods
Subjects and treatments.
Dopamine-deficient (Th −/−;DbhTh /+) mice carrying two inactive Tyrosine hydroxylase (Th) alleles, one intact Dopamine β-hydroxylase allele (Dbh +), and one Dbh allele with a targeted insertion of the Th gene (DbhTh ) were created as described previously (Zhou and Palmiter, 1995). Beginning at approximately postnatal day 10, DD mice received daily injections of l-dopa to induce feeding. Controls included animals that carry at least one intact Th allele and one intact Dbh allele. Mice were backcrossed several generations and are >90% C57BL/6 (<10% 129/SvEv). Attempts to backcross further were thwarted by declining birth rates and increased DD mortality. All mice were housed under a 12 h light/dark cycle and temperature-controlled environment with food (5LJ5; Purina, St. Louis, MO) and water available ad libitum. All drugs were obtained from Sigma (St Louis, MO), dissolved in vehicle (0.9% saline), and administered at a volume of 10 μl/g (except l-dopa). Treatments included l-dopa (i.p.), caffeine (i.p.), saline (s.c.), cocaine (s.c.), amphetamine (i.p.), SCH-23390 (i.p.), fluoxetine (s.c.), methiothepin (i.p.), and quinpirole (i.p.). l-Dopa (1.5 mg/ml) and ascorbic acid (2.5 mg/ml) were dissolved in PBS (33 μl/g to deliver l-dopa at 50 mg/kg). All mice were treated in accordance with guidelines established by the National Institutes of Health and the University of Washington Animal Care Committee.
Conditioned place preference.
All CPP experiments were conducted using Plexiglas three-chamber boxes with two equal-sized compartments (20 × 20 cm) separated by a neutral gray chamber (20 × 7.5 cm). The boxes were separated by two sliding doors. The two large compartments had different-colored walls (black or white) and different flooring (hard punched metal or stiff wire mesh) and were cued with different scents beneath the flooring (clove or ginger). The boxes were balanced such that mice averaged equal amounts of time spent in both large chambers during pretest sessions. Each animal was assigned one compartment for saline pairing and the other compartment for cocaine pairing. The groups were balanced such that each group averaged equal amounts of time in each of the assigned conditioning compartments (i.e., an unbiased paradigm). CPP experiments were performed essentially as described previously (Hnasko et al., 2005). Briefly, on the pretest day (16–23 h after l-dopa), mice were pretreated with caffeine (15 mg/kg) to enable locomotion 5 min before being placed in the center chamber and allowed to explore the entire apparatus for 25 min. These sessions were recorded using a digital video camera (Sony, Tokyo, Japan). Videos were analyzed using Ethovision software (Noldus, Wageningen, The Netherlands) to determine the time spent in each compartment. Any animal that spent >65% of their time in either large compartment or >40% of their time in the neutral middle compartment were discarded from the study before assigning sides, because of the confounding factor of an endogenous preference or aversion. On pairing days, each day each animal was treated with saline and confined to one side for 25 min in the morning and treated with drug and confined to the opposite side for 25 min in the afternoon. Conditioning drugs included cocaine, fluoxetine, SCH-23390, methiothepin, and quinpirole, and there was a delay of 0, 0, 10, 30, or 15 min, respectively, after drug treatment before placement in the conditioning chambers. Morning and afternoon conditioning sessions began 16–18 h or 19–21 h after the previous day's l-dopa treatment, respectively, and mice received l-dopa no sooner than 1 h after the afternoon conditioning treatment. Thus, all pairing sessions were conducted in the dopamine-depleted state and in the absence of caffeine. After 3 d of conditioning, a posttest session was conducted identically to the pretest. Data represent the percentage of time spent in the drug-paired, compared with the saline-paired, compartment before and after conditioning (i.e., the ratio does not include time spent in the unpaired center chamber).
The experiments with SCH-23390, quinpirole, methiothepin, and amphetamine pretreatments required extending conditioning sessions over 6 d, alternating one saline (days 2, 4, and 6) or drug (days 3, 5, and 7) session per day. SCH-23390 (10 μg/kg), methiothepin (30 μg/kg), or quinpirole (50 μg/kg) were administered ∼18 h after l-dopa and 10, 30, and 15 min, respectively, before conditioning treatments (i.e., saline, cocaine, or fluoxetine). Mice received l-dopa no sooner than 3 h after conditioning treatments. For the experiments with amphetamine, mice were treated with amphetamine (3 mg/kg) in their home cages and 3 h later mice received saline or cocaine (10 mg/kg) in conditioning chambers. Baseline and testing sessions were performed as described above except that testing was performed on day 8.
Results
Cocaine elicits CPP by DD mice
DD mice are severely hypoactive and do not readily explore a conditioning chamber. However, caffeine stimulates locomotion by DD mice, and caffeine treatment is sufficient to induce the locomotor activity required to explore a CPP box (Hnasko et al., 2005). Thus, DD and littermate-control mice were treated with caffeine during baseline and testing sessions of our CPP paradigm, but saline- and cocaine-pairing sessions were performed in the absence of caffeine. Under these conditions, control mice formed a significant CPP for cocaine at doses ranging from 5 to 15 mg/kg (Fig. 1 A). DD mice also developed a CPP for cocaine, but only at doses of 7.5 and 10 mg/kg (Fig. 1 A). DD mice received cocaine 19–23 h after previous l-dopa injections, at which time brain dopamine levels are <1% of control levels (Szczypka et al., 1999). However, because dopamine receptors in DD mice are hypersensitive (Kim et al., 2000), this residual dopamine has the potential to be behaviorally relevant. We have previously presented evidence that amphetamine treatment depletes this residual dopamine (Heusner et al., 2003). Therefore, to ensure that residual dopamine was not responsible for mediating cocaine CPP in DD mice, we treated mice with amphetamine 3 h before each pairing session. Amphetamine pretreatment did not disrupt preference for 10 mg/kg cocaine in either control or DD mice (Fig. 1 B), demonstrating that residual dopamine is not necessary for cocaine CPP in DD mice. Furthermore, pretreatment with SCH-23390 (10 μg/kg), a D1-receptor antagonist, did not block cocaine CPP in DD mice, although it blocked preference in control mice (Fig. 1 C), as has been previously reported (Cervo and Samanin, 1995; Pruitt et al., 1995). This dose of SCH-23390 did not independently induce preference or aversion in DD mice (percentage time on SCH-23390-paired chamber during pretest = 49.6 ± 4.7%; posttest = 54.7 ± 10.0%; n = 6). These results indicate that moderate doses of cocaine can elicit CPP in the absence of dopamine signaling in DD mice.
Serotonin mediates CPP by DD mice
To determine whether the rewarding effects of cocaine in DD mice could be caused by increased serotonin signaling resulting from cocaine-mediated SERT blockade, we tested the effects of fluoxetine, a selective serotonin reuptake inhibitor, in our CPP paradigm. A dose–response experiment performed using control mice revealed that fluoxetine produced significant conditioned place aversion (CPA) at 15 or 10 mg/kg, but not at 5 mg/kg (Fig. 2 A). We therefore tested DD mice with fluoxetine at 5 mg/kg and observed robust CPP (Fig. 2 B). These results suggest that in the absence of dopamine, SERT blockade mediates reward, and provides a plausible mechanism for cocaine-mediated CPP in DD mice.
In addition, pretreatment with the 5-HT1 receptor antagonist methiothepin (30 μg/kg) blocked the formation of CPP for cocaine (Fig. 2 D) and fluoxetine (Fig. 2 E). This dose of methiothepin did not independently induce a significant preference or aversion in DD mice (Fig. 2 C), although a trend toward aversion was observed, which became significant at higher doses in control mice (data not shown).
Dopamine D2-receptor activation abolishes cocaine and fluoxetine CPP by DD mice
Because multiple lines of evidence suggest that dopamine neurons are critical for reward learning in general and for cocaine reward in particular (Schultz, 2002; Wise, 2004; Pierce and Kumaresan, 2006), and because dopamine neurons release transmitters other than dopamine, we sought to explore the hypothesis that dopamine neurons are necessary for CPP even in the absence of dopamine release. To do this, we tested the effects of quinpirole (50 μg/kg), a dose that inhibits dopamine neuron activity in DD mice (Robinson et al., 2004). First, we demonstrated that quinpirole alone (at 50 μg/kg) produces no substantial preference or aversion (Fig. 3 A). However, when control or DD mice were treated with quinpirole before pairing, cocaine CPP was abolished (Fig. 3 B). Indeed, quinpirole pretreatment resulted in cocaine-induced CPA in control mice. Because we observed that SERT blockade was sufficient to mediate CPP in DD mice, we also tested the effect of quinpirole on fluoxetine-mediated CPP. Quinpirole pretreatment also blocked fluoxetine CPP in DD mice (Fig. 3 C). These experiments suggest that dopamine neuron activity may be critical for cocaine- and fluoxetine-mediated CPP, even when dopamine is not.
Discussion
We have shown that DD mice are capable of forming a CPP for cocaine, although within a narrowed dose range. We demonstrate that this cocaine CPP is independent of any remaining residual dopamine and is unaffected by a D1-receptor antagonist that blocks CPP in control mice. Our finding that fluoxetine can also produce CPP in DD mice, but not controls, suggests that increased serotonin signaling mediates cocaine CPP by DD mice. Finally, inhibition of dopamine neuron activity with a low dose of the D2-receptor agonist, quinpirole, is sufficient to block both cocaine and fluoxetine CPP by DD mice. We suggest that cocaine activates dopamine neurons through increased serotonin in DD mice and that dopamine neurons release an alternative neuromodulator that is critical for CPP.
The observation that cocaine elicits CPP in the absence of dopamine is curious in light of the ability of D1-receptor antagonists to attenuate cocaine CPP in normal animals (Fig. 1 C). However, DD mice only showed cocaine preference at intermediate doses of cocaine (7.5 and 10 mg/kg). One potential explanation for this result is that cocaine reward is comprised of both dopamine-dependent and dopamine-independent components. The lack of CPP at low doses of cocaine may then indicate that the dopamine-independent pathway is not yet sufficiently engaged. The lack of CPP for high doses of cocaine likely reflects a predominance of the aversive effects of cocaine, which presumably occur at lower doses in the absence of dopamine. Thus, after acute cocaine treatment, dopamine release may augment the action of some other neurotransmitter and thereby broaden responsiveness to the hedonic impact or strengthen the associative learning processes that are required for CPP.
SERT blockade mediates CPP by DD mice
Because fluoxetine induced CPP in DD mice, the mechanism by which cocaine produces reward in the absence of dopamine is likely through increased serotonin signaling, despite the fact that acute SERT blockade can be aversive in normal animals (Fig. 2 A). This conclusion is also supported by our observation that blockade of 5-HT1 receptors disrupts the formation of CPP for both cocaine and fluoxetine. Although 5-HT1 receptors are widespread throughout the brain, others have provided evidence that mesolimbic dopamine neurons serve as a locus at which cocaine-induced increases in 5-HT1 signaling activate dopamine neurons (Johnson et al., 1992; Cameron and Williams, 1994) and contribute to cocaine reward (Neumaier et al., 2002; David et al., 2004). However, in the absence of dopamine, how does SERT blockade mediate CPP? There is an interesting parallel with DAT-KO mice, which also retained cocaine CPP (Rocha et al., 1998a; Sora et al., 1998) and acquired CPP for serotonin-reuptake blockers (Hall et al., 2002; Mateo et al., 2004). In DAT-KO mice, cocaine still increased dopamine levels in the ventral (but not dorsal) striatum (Carboni et al., 2001; Mateo et al., 2004), and this increase has been offered as an explanation for their retention of cocaine CPP. Because DAT/SERT double-KO mice lack cocaine CPP (Sora et al., 2001), and because fluoxetine infusion directly into the ventral tegmental area (VTA) also increased extracellular dopamine in the NAc (Mateo et al., 2004), Mateo et al. (2004) suggested that cocaine-induced increases in serotonin signaling in the VTA activated dopamine neurons in DAT-KO mice. The chronically elevated levels of dopamine in the DAT-KO mice may have promoted a “switch” such that the net effect of increased serotonin signaling on to VTA dopamine neurons becomes excitatory. Although it may seem paradoxical, a similar mechanism could occur in DD mice, because DD mice are hyperdopaminergic for a few hours each day. Each daily injection of l-dopa elicits robust behavioral and molecular responses. For example, there is a dramatic induction of c-fos in the striatum (and elsewhere) that is comparable with that observed when control mice are given cocaine or amphetamine (Kim et al., 2000). These spikes of dopamine signaling may promote adaptations in the serotonin system similar to those in DAT-KO mice.
Mice bearing a mutant DAT that has essentially normal dopamine uptake activity, but does not bind cocaine, were shown to lack cocaine CPP (Chen et al., 2006). That result supports the conclusion that cocaine CPP observed in DAT-KO mice is a compensatory response to chronically elevated dopamine tone. However, the mice with mutated DAT were only tested for CPP at cocaine doses of 5 and 20 mg/kg (Chen et al., 2006), doses that failed to produce CPP in our DD mice and also failed to produce CPP by inbred DAT-KO mice (Medvedev et al., 2005), whereas intermediate doses were effective in both models.
Are dopamine neurons required for cocaine CPP by DD mice?
We suggest that activity of dopamine neurons may still be important for cocaine CPP by DD mice even if they do not release dopamine, because quinpirole blocked both cocaine- and fluoxetine-mediated CPP. The firing rate of dopamine neurons of DD mice (measured in awake behaving mice) was inhibited by low doses of the D2-receptor agonist, quinpirole (Robinson et al., 2004). Quinpirole also blocked cocaine CPP in control mice, as might be expected as a result of activation of D2 autoreceptors on dopamine neurons and/or feedback via the indirect pathway. However, in addition to inhibiting dopamine neurons, quinpirole could directly affect acquisition or expression of CPP through activation of postsynaptic receptors. However, we are encouraged by the observations that the low dose of quinpirole we used had neither rewarding nor aversive effects by itself, but blocked both cocaine- and fluoxetine-mediated CPP. Definitive evidence that dopamine neuron activity is required for cocaine CPP will require a method for selectively silencing dopamine neurons.
If dopamine neuron activity is required for cocaine CPP in the absence of dopamine release, this would provide strong evidence that these neurons release other neuromodulators with biologically significant effects. Neuropeptides such as cholecystokinin and neurotensin are released by dopamine neurons and are capable of modulating behavioral responses to drugs of abuse (Geisler et al., 2006; Mitchell et al., 2006). In addition, emerging evidence suggests that glutamate is coreleased from dopamine neurons (Chuhma et al., 2004; Lavin et al., 2005). Thus, we suggest that in DD mice there are compensatory changes that allow cocaine-induced increases in serotonin to activate dopamine neurons, causing release of a nondopamine transmitter. The subsequent activation of nondopamine postsynaptic receptors in the striatum or other brain regions may then be essential for cocaine CPP in DD mice.
Footnotes
-
T.S.H. was supported in part by National Institute of General Medical Sciences Grant PHS NRSA T32 GM07270. This work was supported in part by National Institutes of Health Grant P50-DA13410. We thank Nora Meneses for help maintaining the DD mouse colony and Charles Chavkin and Larry Zweifel for their input during the preparation of this manuscript.
- Correspondence should be addressed to Richard D. Palmiter, Howard Hughes Medical Institute, Box 357370, University of Washington, Seattle, WA 98195. palmiter{at}u.washington.edu